Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PALISADE BIO, INC.
Report date February 08, 2024 · Filed February 13, 2024
Section 16 reporting ended · disclosed 2024-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01SEC Table I · non-derivative | Direct | 10,920 |
Last balance in matching sequence
After 2024-02-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-02-08 · Exercise / conversion · Acquired 5,100 · Balance 5,100 F1: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. Row 2 · 2024-02-08 · Exercise / conversion · Acquired 5,820 · Balance 10,920 F1: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. F2: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-08 · Exercise / conversion · Disposed 5,100 · Balance 0 F3: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding. F5: Each restricted stock unit represents the right to receive one share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-08 · Exercise / conversion · Disposed 5,820 · Balance 0 F4: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding. F5: Each restricted stock unit represents the right to receive one share of common stock. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-06-11 | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-08 · Exercise / conversion · Disposed 12,160 · Balance 0 F6: Each option represents the right to purchase one share of common stock at the exercise price. F7: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-06-11 | Direct | 12,160 |
Reported balance
After 2024-02-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-08 · Exercise / conversion · Acquired 12,160 · Balance 12,160 F6: Each option represents the right to purchase one share of common stock at the exercise price. F7: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-11-21 | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-08 · Exercise / conversion · Disposed 6,880 · Balance 0 F6: Each option represents the right to purchase one share of common stock at the exercise price. F8: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-11-21 | Direct | 6,880 |
Reported balance
After 2024-02-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-08 · Exercise / conversion · Acquired 6,880 · Balance 6,880 F6: Each option represents the right to purchase one share of common stock at the exercise price. F8: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F2: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F3: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding.
F4: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding.
F5: Each restricted stock unit represents the right to receive one share of common stock.
F6: Each option represents the right to purchase one share of common stock at the exercise price.
F7: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F8: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · derivative · entry 8 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F8 · security: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · derivative · entry 7 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F8 · security: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 12,160 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · derivative · entry 6 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,160 Underlying: Common Stock · 12,160 shares Expires 2033-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F7 · security: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 12,160 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · derivative · entry 5 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,160 shares Expires 2033-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F7 · security: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · derivative · entry 4 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding. F4 · derivative.exercise_price: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of common stock. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · derivative · entry 3 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding. F3 · derivative.exercise_price: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of common stock. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · nonDerivative · entry 2 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. F2 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 15:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006050 · ownership.xml · nonDerivative · entry 1 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 16:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-23-042665 · ownership.xml · derivative · entry 2 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 16:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-042665 · ownership.xml · derivative · entry 1 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 5,820 shares Expires not disclosed F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F3 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 17:15 UTC | PALISADE BIO, INC. PALI · Entity 5803 | SaleCommon Stock, par value $0.01 | 300 | $0.64 | $192.00 |
DisclosureSEC source: 0001493152-23-032794 · ownership.xml · nonDerivative · entry 1 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects the weighted average sale price. The range of prices for such transaction was $0.6396 to $0.6507. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F1 · price: Reflects the weighted average sale price. The range of prices for such transaction was $0.6396 to $0.6507. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 18:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 12,160 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-23-021133 · ownership.xml · derivative · entry 2 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,160 Underlying: Common Stock · 12,160 shares Expires 2033-06-11 F1 · security: Represents partial compensation for services as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 5,160 common stock purchase options as a discretionary grant. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 18:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-021133 · ownership.xml · derivative · entry 1 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 5,100 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 5,160 common stock purchase options as a discretionary grant. F3 · security: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A Read SEC document |
| November 18, 2021 Filed Feb 10, 2022 18:26 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (right to buy) · Derivative | 48,340 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-008586 · doc4.xml · derivative · entry 1 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,340 Underlying: Common Stock · 48,340 shares Expires 2032-11-17 F1 · derivative.exercise_date: 25% of the shares of Common Stock subject to the Option shall vest on each quarterly anniversary of the grant date over a one-year period. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 18:40 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 2,142 | $2.98 | $6,383.16 |
DisclosureSEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 5 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,999 Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 18:40 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 3,400 | $2.89 | $9,826.00 |
DisclosureSEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 4 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,857 Read SEC document |
| September 08, 2021 Filed Sep 13, 2021 18:40 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 5,000 | $2.75 | $13,750.00 |
DisclosureSEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 3 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,457 Read SEC document |
| September 07, 2021 Filed Sep 13, 2021 18:40 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 2,707 | $2.78 | $7,525.46 |
DisclosureSEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 2 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,457 Read SEC document |
| August 31, 2021 Filed Sep 13, 2021 18:40 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 1,750 | $2.75 | $4,812.50 |
DisclosureSEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 1 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 17:55 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantWarrant (right to buy) · Derivative | 1,223 | Not disclosed Strike: $26.85 | Not disclosed |
DisclosureSEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 7 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Yuma Regional Medical Center Disclosed balance after: 1,223 Underlying: Common Stock · 1,223 shares Expires 2030-10-15 F11 · price: Received in the Merger in exchange for a warrant to purchase 45,000 shares of LBS common stock for $0.73 per share. F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 17:55 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantWarrant (right to buy) · Derivative | 13,595 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 6 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Yuma Regional Medical Center Disclosed balance after: 13,595 Underlying: Common Stock · 13,595 shares Expires 2029-08-15 F10 · price: Received in the Merger in exchange for a warrant to purchase 500,000 shares of LBS common stock for $1.12 per share. F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 17:55 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantWarrant (right to buy) · Derivative | 40,785 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 5 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Yuma Regional Medical Center Disclosed balance after: 40,785 Underlying: Common Stock · 40,785 shares Expires 2029-03-08 F9 · price: Received in the Merger in exchange for a warrant to purchase 1,500,000 shares of LBS common stock for $1.12 per share. F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 17:55 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 4,406 | Not disclosed Strike: $26.85 | Not disclosed |
DisclosureSEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 4 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,406 Underlying: Common Stock · 4,406 shares Expires 2030-07-10 F8 · price: Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share. F7 · derivative.exercise_date: The stock option vests according to the following schedule: 25% of the shares underlying the option vests on the grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning on September 30, 2020. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 17:55 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 1,298 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 3 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298 Underlying: Common Stock · 1,298 shares Expires 2029-06-19 F6 · price: Received in the Merger in exchange for a stock option to acquire 47,758 shares of LBS common stock for $1.12 per share. F5 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 17:55 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 10,182 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 2 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,182 Underlying: Common Stock · 10,182 shares Expires 2029-04-25 F4 · price: Received in the Merger in exchange for a stock option to acquire 374,500 shares of LBS common stock for $1.12 per share. F3 · derivative.exercise_date: The stock option vested according to the following schedule: 25% of the shares underlying the option vested on the grant date and the remaining 75% vested in three equal quarterly installments thereafter beginning on June 30, 2019. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 17:55 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock | 304,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029080 · doc4.xml · nonDerivative · entry 1 Trenschel Robert J. · CIK 0001849917 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Yuma Regional Medical Center Disclosed balance after: 304,479 F1 · price: Received in exchange for 11,198,208 shares of common stock of Leading BioSciences, Inc. ("LBS"), pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc. F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.